Open University of Cyprus, Health Care Management Programme , Cyprus , Europe.
Expert Opin Pharmacother. 2015 Jun;16(8):1233-43. doi: 10.1517/14656566.2015.1039982.
The Oncology field is characterised by a steady increase in demand and a consistent launching of innovative and expensive products. Therefore, cost-effectiveness analysis can contribute as a significant decision-making tool by elucidating the most economically efficient ways to satisfy compelling health needs.
The scope of this study is to estimate the cost-effectiveness of axitinib versus sorafenib, for the second-line treatment of renal cell carcinoma. A literature review for evidence synthesis was performed and a probabilistic Markov Model was employed to simulate disease progression. This study will also assess Value of Information.
Compared to sorafenib, axitinib resulted in an incremental cost of 87,936 euro per quality adjusted life year. The probability of axitinib to being cost-effective at the willingness-to-pay threshold of 60,000 euro was 13%, while the corresponding probability of being cost-effective at the highest recommended willingness-to-pay threshold of 100,000 euro was 69.9%. Uncertainty was primarily attributed to the price of the product, the utility values, the progression-free survival and to a lesser degree to the overall survival. Axitinib can be considered as a cost-effective therapeutic option for second-line treatment of renal cell carcinoma.
肿瘤学领域的特点是需求稳步增长，并且不断推出创新和昂贵的产品。因此，成本效益分析可以作为一个重要的决策工具，阐明满足迫切健康需求的最具经济效益的方法。
本研究旨在评估阿昔替尼与索拉非尼相比在二线治疗肾细胞癌方面的成本效益。进行了文献综述以进行证据综合，并采用概率马尔可夫模型来模拟疾病进展。本研究还将评估信息价值。
与索拉非尼相比，阿昔替尼每增加一个质量调整生命年的成本为 87936 欧元。在愿意支付的 60000 欧元阈值下，阿昔替尼具有成本效益的概率为 13%，而在最高推荐的 100000 欧元愿意支付的阈值下具有成本效益的概率为 69.9%。不确定性主要归因于产品价格、效用值、无进展生存期，在较小程度上归因于总生存期。阿昔替尼可被视为二线治疗肾细胞癌的一种具有成本效益的治疗选择。
